Skip to main content

Advertisement

SpringerLink
Log in

Mucinous Gastric Cancer Presents with More Advanced Tumor Stage and Weaker β-Catenin Expression than Nonmucinous Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Mucinous gastric carcinoma (MGC) is a rare type of gastric cancer; its biological behavior is controversial. In this study, we attempted to clarify the clinical and pathological features as well as the prognostic significance of MGC. We also compared the expression patterns of CDX-2 and β-catenin between MGC and nonmucinous gastric carcinoma (NMGC).

Methods

We reviewed the records of 9218 patients with gastric cancer who underwent gastric cancer surgery between January 1997 and December 2006. The clinicopathological features and clinical outcome of MGC (n = 197) were compared to NMGC (n = 9021). Immunohistochemical staining using the tissue array method was performed on MGC (n = 194) and NMGC (n = 89) tissues.

Results

MGC had a larger size and a higher frequency of Borrmann type I findings in advanced cases than NMGC. In addition, MGC had deeper invasion, more lymph node and lymphatic involvement, a more advanced tumor stage, and lower 5-year survival rates than NMGC. Age, depth of invasion, lymph node metastasis, lymphatic invasion, and curability were independent prognostic factors; but the mucinous histological type itself was not predictive of outcome. β-Catenin immunoreactivity was statistically significantly weaker in MGC than NMGC; however, there was no difference in CDX-2 expression between the two groups.

Conclusions

MGC presents at a more advanced stage and was larger than NMGC. The poor prognosis of MGC was related to the more advanced tumor stage at diagnosis; the histological type was not an independent prognostic factor. The result of immunohistochemical staining suggests that MGC has a distinct pathway of carcinogenesis from NMGC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Shin HR, Ahn YO, Bae JM, Shin MH, et al. Cancer incidence in Korea. Cancer Res Treat. 2002;34:405–8.

    Google Scholar 

  2. Adachi Y, Mori M, Kido A, et al. A clinicopathologic study of mucinous gastric carcinoma. Cancer. 1992;69:866–71.

    Article  CAS  PubMed  Google Scholar 

  3. Kawamura H, Kondo Y, Osawa S, et al. A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 2001;4:83–6.

    Article  CAS  PubMed  Google Scholar 

  4. Woo LS, Kim DY, Kim YJ, Kim SK. Clinicopathologic features of mucinous gastric carcinoma. Dig Surg. 2002;19:286–90.

    Article  CAS  PubMed  Google Scholar 

  5. Kunisaki C, Akiyama H, Nomura M, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol. 2006;13:836–42.

    Article  PubMed  Google Scholar 

  6. Wu CY, Yeh HZ, Shih RT, Chen GH. A clinicopathologic study of mucinous gastric carcinoma including multivariate analysis. Cancer. 1998;83:1312–8.

    Article  CAS  PubMed  Google Scholar 

  7. Yasuda K, Adachi Y, Shiraishi N, et al. Pathology and prognosis of mucinous gastric carcinoma. J Surg Oncol. 2001;76:272–7.

    Article  CAS  PubMed  Google Scholar 

  8. Hyung WJ, Noh SH, Shin DW, et al. Clinicopathologic characteristics of mucinous gastric adenocarcinoma. Yonsei Med J. 1999;40:99–106.

    CAS  PubMed  Google Scholar 

  9. Adachi Y, Yasuda K, Inomata M, et al. Clinicopathologic study of early-stage mucinous gastric carcinoma. Cancer. 2001;91:698–703.

    Article  CAS  PubMed  Google Scholar 

  10. Yasuda K, Shiraishi N, Inomata M, et al. Clinicopathologic characteristics of early-stage mucinous gastric carcinoma. J Clin Gastroenterol. 2004;38:507–11.

    Article  PubMed  Google Scholar 

  11. Adachi Y, Yasuda K, Kitano S. Mucinous gastric carcinoma: is it more malignant? Gastric Cancer. 2001;4:223–4.

    Article  CAS  PubMed  Google Scholar 

  12. Yamamichi N, Inada K, Ichinose M, et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res. 2007;67:10727–35.

    Article  CAS  PubMed  Google Scholar 

  13. Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri AS. The links between transcription, beta-catenin/JNK signaling, and carcinogenesis. Mol Cancer Res. 2009;7:1189–96.

    Article  CAS  PubMed  Google Scholar 

  14. Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion. 2002;66:131–44.

    Article  CAS  PubMed  Google Scholar 

  15. Mizoshita T, Inada K, Tsukamoto T, et al. Expression of Cdx1 and Cdx2 mRNAs and relevance of this expression to differentiation in human gastrointestinal mucosa—with special emphasis on participation in intestinal metaplasia of the human stomach. Gastric Cancer. 2001;4:185–91.

    Article  CAS  PubMed  Google Scholar 

  16. Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004;3:593–601.

    Article  CAS  PubMed  Google Scholar 

  17. Bai YQ, Yamamoto H, Akiyama Y, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47–55.

    Article  CAS  PubMed  Google Scholar 

  18. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res. 1996;56:49–52.

    CAS  PubMed  Google Scholar 

  19. Park WS, Oh RR, Park JY, et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999;59:4257–60.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Min-Gew Choi MD, Jae Hyung Noh MD, Tae Sung Sohn MD, Sung Kim MD & Jae Moon Bae MD, PhD

  2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Chang Ohk Sung MD & Kyoung-Mee Kim MD

Authors
  1. Min-Gew Choi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang Ohk Sung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae Hyung Noh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyoung-Mee Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tae Sung Sohn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sung Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jae Moon Bae MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Moon Bae MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, MG., Sung, C.O., Noh, J.H. et al. Mucinous Gastric Cancer Presents with More Advanced Tumor Stage and Weaker β-Catenin Expression than Nonmucinous Cancer. Ann Surg Oncol 17, 3053–3058 (2010). https://doi.org/10.1245/s10434-010-1184-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1184-z

Keywords

Search

Navigation